Related Experiment Video
Updated: Feb 12, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Low-density lipoprotein-cholesterol lowering in individuals at intermediate cardiovascular risk: Percent reduction or
Fernando H Y Cesena1, Antonio Gabriele Laurinavicius1, Viviane A Valente1
1Hospital Israelita Albert Einstein, São Paulo, Brazil.
Insights
For intermediate-risk individuals, a 40% low-density lipoprotein-cholesterol (LDL-c) reduction strategy offers greater cardiovascular benefit than a fixed LDL-c target. Tailoring treatment or using a dual-target approach optimizes outcomes.
Area of Science:
- Cardiology
- Preventive Medicine
- Lipid Metabolism
Background:
- Cholesterol management guidelines vary.
- Lipid-lowering strategies may yield different cardiovascular benefits in intermediate-risk groups.
Purpose of the Study:
- To compare the cardiovascular benefits of LDL-c percent reduction versus a target concentration in intermediate-risk individuals.
- To evaluate the effectiveness of different LDL-c lowering strategies for preventing major cardiovascular events.
Main Methods:
- Simulated two LDL-c lowering strategies (40% reduction vs. ≤100 mg/dL target) in 1756 individuals (40-75 years) with 5-7.5% 10-year ASCVD risk.
- Estimated cardiovascular benefit using a 22% relative risk reduction per 39 mg/dL LDL-c decrease.
Main Results:
- The 40% LDL-c reduction strategy (S40%) showed a lower number needed to treat (NNT10=56) than the target strategy (NNT10=66).
- S40% was more effective for lower baseline LDL-c, while the target strategy was better for higher baseline LDL-c.
- A dual-target strategy yielded similar results to S40% (NNT10=55).
Conclusions:
- Optimizing cardiovascular benefit in intermediate-risk populations can be achieved by tailoring LDL-c lowering based on baseline levels.
- A dual-target strategy (e.g., fixed statin dose plus LDL-c target achievement) is a viable approach to enhance treatment outcomes.
Background:
Recommendations for blood cholesterol management differ across different guidelines.
Hypothesis:
Lipid-lowering strategies based on low-density lipoprotein-cholesterol (LDL-c) percent reduction or target concentration may have different effects on the expected cardiovascular benefit in intermediate-risk individuals.
Methods:
We selected individuals between 40 and 75 years of age with 10-year risk for atherosclerotic cardiovascular disease (ASCVD) between 5.0% and <7.5% who underwent a routine health screening. For every subject, we simulated a strategy based on a 40% LDL-c reduction (S40% ) and another strategy based on achieving LDL-c target ≤100 mg/dL (Starget-100 ). The cardiovascular benefit was estimated assuming a 22% relative risk reduction in major cardiovascular events for each 39 mg/dL of LDL-c lowered.
Results:
The study comprised 1756 individuals (94% men, 52 ± 5 years old). LDL-c and predicted 10-year ASCVD risk would be slightly lower in S40% compared to Starget-100 . The number needed to treat to prevent 1 major cardiovascular event in 10 years (NNT10 ) would be 56 with S40% and 66 with Starget-100 . S40% would prevent more events in individuals with lower baseline LDL-c, whereas Starget-100 would be more protective in those with higher LDL-c. A dual-target strategy (40% minimum LDL-c reduction and achievement of LDL-c ≤100 mg/dL) would be associated with outcomes similar to those expected with the S40% (NNT10 = 55).
Conclusions:
In an intermediate-risk population, cardiovascular benefit from LDL-c lowering may be optimized by tailoring the treatment according to the baseline LDL-c or by setting a dual-target strategy (fixed dose statin plus achievement of target LDL-c concentration).
Related Concept Videos
Vapor Pressure Lowering
Bond Polarity, Dipole Moment, and Percent Ionic Character
Cholesterol: Significance and Regulation
Considering cholesterol and...
The Intermediate Value Theorem
Oxidation-Reduction Reactions
Disassembly of Intermediate Filaments
Keratin proteins, found at the cell periphery near cell junctions, undergo a cycle of assembly and disassembly. In Type...

